Cefpodoxime: Difference between revisions
| Line 28: | Line 28: | ||
==Special Populations== | ==Special Populations== | ||
*[[Drug Ratings in Pregnancy|Pregnancy Rating]]: | *[[Drug Ratings in Pregnancy|Pregnancy Rating]]: B | ||
*Lactation: | *Lactation: excreted in breast milk, not recommended for nursing women | ||
*Renal Dosing | *Renal Dosing | ||
**Adult | **Adult | ||
***CrCl >30 mL/minute: dose adjustment not needed | |||
***CrCl <30 mL/minute: administer q 24 h | |||
***Hemodialysis: 3 times/week following dialysis | |||
**Pediatric | **Pediatric | ||
*Hepatic Dosing | *Hepatic Dosing | ||
Revision as of 16:16, 13 June 2016
General
- Type: 3rd generation cephalosporin
- Dosage Forms: tablet (100,200), suspension (50 mg/5ml, 100 mg/5ml)
- Common Trade Names: Cefopodoxine Proxetil
Adult Dosing
- Bronchitis (chronic), actue bacterial infection: 200 mg q 12 h for 10 days
- Pharyngitis/Tonsillitis: 100 mg q 12 h for 5-10 days
- Acute community acquired pneumonia: 200 mg q 12 h for 14 days
- Acute rhino sinusitis: 200 mg q 12 h for 10 days
- Skin and soft tissue infection: 400 mg q 12 h for 14 days
- Urinary tract infection, uncomplicated: 100 mg q 12 h for 7 days
Pediatric Dosing
- General range
- Infant ≥2 months to children <12 years: 10 mg/kg/day (maximum 200 mg/dose) q 12 h
- Children >12 years to adolescent: 100 to 400 mg q 12 h
- Specific indication
- Bronchitis (chronic), acute bacterial infection: adult dosing for Infant ≥2 months to children <12 years
- Acute otitis media: Infant ≥2 months to children <12 years: 5 mg/kg/dose (maximum 200 mg/dose) q 12 h for 5 days, duration according to AAP recommendation [1]: for children < 2 years or any age with sever symptoms; 10 day-course, age 2-5 years with mild to moderate symptoms: 7 day-course; age ≥ 6 years with mild to moderate symptoms: 5 day-course
- Pharyngitis/tonsillitis:
- Infant ≥2 months to children <12 years: 5 mg/kg/dose (maximum 100 mg/dose) q 12 h for 5-10 days
- Children >12 years to adolescent: adult dosing
- Acute sinusitis
- Infant ≥2 months to children <12 years: 5 mg/kg/dose (maximum 200 mg/dose) q 12 h for 10 days, ISDA recommend adding Clindamycin for 10-14 days in patients with failed initial therapy or at risk of antibiotic resistance (attending daycare, age <2 years, recently hospitalised, antibiotic used with in 1 month) [2]
- Children >12 years to adolescent: adult dosing
- skin soft tissue infection and uncomplicated urinary tract infection: children >12 years to adolescent: adult dosing
Special Populations
- Pregnancy Rating: B
- Lactation: excreted in breast milk, not recommended for nursing women
- Renal Dosing
- Adult
- CrCl >30 mL/minute: dose adjustment not needed
- CrCl <30 mL/minute: administer q 24 h
- Hemodialysis: 3 times/week following dialysis
- Pediatric
- Adult
- Hepatic Dosing
- Adult
- Pediatric
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
Common
Pharmacology
- Half-life:
- Metabolism:
- Excretion:
- Mechanism of Action:
